Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 315

The DOI matches its Crossref record; 147 of the 147 references it cites were found in a registry or an index.

Type 2 inflammation in asthma and other airway diseases

Open access
Maspero, Jorge, Adir, Yochai, Al-Ahmad, Mona, Celis-Preciado, Carlos A., Colodenco, Federico D., Giavina-Bianchi, Pedro, Lababidi, Hani, Ledanois, Olivier, Mahoub, Bassam, Perng, Diahn-Warng, Vazquez, Juan C., Yorgancioglu, Arzu·2022·ERJ Open Research

Abstract

Chronic inflammatory airway diseases, including asthma, chronic rhinosinusitis, eosinophilic COPD and allergic rhinitis are a global health concern. Despite the coexistence of these diseases and their common pathophysiology, they are often managed independently, resulting in poor asthma control, continued symptoms and poor quality of life. Understanding disease pathophysiology is important for best treatment practice, reduced disease burden and improved patient outcomes. The pathophysiology of type 2 inflammation is driven by both the innate immune system triggered by pollutants, viral or fungal infections involving type 2 innate lymphoid cells (ILC2) and the adaptive immune system, triggered by contact with an allergen involving type 2 T-helper (Th2) cells. Both ILC2 and Th2 cells produce the type-2 cytokines (interleukin (IL)-4, IL-5 and IL-13), each with several roles in the inflammation cascade. IL-4 and IL-13 cause B-cell class switching and IgE production, release of pro-inflammatory mediators, barrier disruption and tissue remodelling. In addition, IL-13 causes goblet-cell hyperplasia and mucus production. All three interleukins are involved in trafficking eosinophils to tissues, producing clinical symptoms characteristic of chronic inflammatory airway diseases. Asthma is a heterogenous disease; therefore, identification of biomarkers and early targeted treatment is critical for patients inadequately managed by inhaled corticosteroids and long-acting β-agonists alone. The Global Initiative for Asthma guidelines recommend add-on biological (anti IgE, IL-5/5R, IL-4R) treatments for those not responding to standard of care. Targeted therapies, including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab and tezepelumab, were developed on current understanding of the pathophysiology of type 2 inflammation. These therapies offer hope for improved management of type 2 inflammatory airway diseases.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/23120541.00576-2021

Cites

147 of 147 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 147 references

Cited by

See all 315

Metadata

Authors
Maspero, J., Adir, Y., Al-Ahmad, M., Celis-Preciado, C. A., Colodenco, F. D., Giavina-Bianchi, P., Lababidi, H., Ledanois, O., Mahoub, B., Perng, D.-W., Vazquez, J. C., & Yorgancioglu, A.
Venue
ERJ Open Research
Published
2022-07
Volume
8
Issue
3
Pages
00576-2021
ISSN
2312-0541 (ISSN-L)
OpenAlex
W4289207146
Cited by
315
References
147
FWCI
29.90
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Type 2 inflammation in asthma and other airway diseases. https://app.cochat.ai/papers/10.1183/23120541.00576-2021
The paper
Maspero, J., Adir, Y., Al-Ahmad, M., Celis-Preciado, C. A., Colodenco, F. D., Giavina-Bianchi, P., Lababidi, H., Ledanois, O., Mahoub, B., Perng, D.-W., Vazquez, J. C., & Yorgancioglu, A. (2022). Type 2 inflammation in asthma and other airway diseases. ERJ Open Research. https://doi.org/10.1183/23120541.00576-2021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.